Targacept Inc (TRGT.O)

TRGT.O on Nasdaq

2.76USD
19 Dec 2014
Price Change (% chg)

$0.24 (+9.52%)
Prev Close
$2.52
Open
$2.44
Day's High
$2.79
Day's Low
$2.44
Volume
279,554
Avg. Vol
141,991
52-wk High
$5.23
52-wk Low
$2.25

TRGT.O

Chart for TRGT.O

About

Targacept, Inc. is a biopharmaceutical company. The Company is engaged in the design, discovery and development of NNR Therapeutics for the treatment of diseases and disorders of the nervous system. The Company's NNR Therapeutics target neuronal nicotinic receptors (NNRs). As of December 31, 2011, the Company had multiple... (more)

Overall

Beta: 1.74
Market Cap (Mil.): $93.67
Shares Outstanding (Mil.): 34.31
Dividend: --
Yield (%): --

Financials

  TRGT.O Industry Sector
P/E (TTM): -- 38.24 38.63
EPS (TTM): -1.23 -- --
ROI: -31.80 19.00 18.26
ROE: -31.86 19.75 19.13
Search Stocks

Targacept discontinues bladder drug, shares plunge

- Targacept Inc said it was stopping development of a drug to treat overactive bladder after it failed to show significant reduction in incontinence in a mid-stage study.

28 Jul 2014

UPDATE 1-Targacept discontinues bladder drug, shares plunge

July 28 - Targacept Inc said it was stopping development of a drug to treat overactive bladder after it failed to show significant reduction in incontinence in a mid-stage study.

28 Jul 2014

Targacept stops development of bladder drug, shares plunge

July 28 - Targacept Inc said it was stopping the development of its bladder drug after it failed to show a statistically significant reduction in episodes of urinary incontinence in a mid-stage study.

28 Jul 2014

Targacept ends Alzheimer's drug trial after mid-stage failure

- Targacept Inc said it was ending a mid-stage trial on its Alzheimer's drug as it did not show superiority over standard medication, sending its shares down as much as 19.8 percent.

14 Jul 2014

UPDATE 1-Targacept ends Alzheimer's drug trial after mid-stage failure

July 14 - Targacept Inc said it was ending a mid-stage trial on its Alzheimer's drug as it did not show superiority over standard medication, sending its shares down as much as 19.8 percent.

14 Jul 2014

Targacept stops Alzheimer's drug trial after it fails mid-stage

July 14 - Targacept Inc said its experimental Alzheimer's drug did not show superiority over standard medication in a mid-stage study and that it would no longer invest in the development of the treatment.

14 Jul 2014

Competitors

  Price Change
Eisai Co., Ltd (4523.T) ¥4,715 -3.00
Pfizer Inc. (PFE.N) $31.42 -0.03
Johnson & Johnson (JNJ.N) $104.59 +0.31
Novartis AG (NOVN.VX) CHF92.35 -1.20
Merck & Co., Inc. (MRK.N) $57.46 +0.25
Roche Holding Ltd. (ROG.VX) CHF270.40 -18.30
Abbott Laboratories (ABT.N) $45.70 -0.02
Sanofi SA (SASY.PA) €74.99 -0.65
AstraZeneca plc (AZN.L) 4,555.50p +39.00
GlaxoSmithKline plc (GSK.L) 1,385.00p 0.00

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ Quantitative Report
$115.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks